PlumX Metrics
Embed PlumX Metrics

A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation for IVF Treatment

Journal of Assisted Reproduction and Genetics, ISSN: 1058-0468, Vol: 22, Issue: 2, Page: 81-88
2005
  • 22
    Citations
  • 0
    Usage
  • 31
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    22
    • Citation Indexes
      20
    • Clinical Citations
      1
      • PubMed Guidelines
        1
    • Policy Citations
      1
      • Policy Citation
        1
  • Captures
    31

Article Description

Purpose: To compare the efficiency and efficacy of two starting doses of recombinant FSH (follitropin-β, Puregon) in women undergoing IVF treatment. Methods: This prospective, randomized, double-blind, multicentric (N = 6) study included 192 women undergoing IVF using the long protocol of GnRH agonist who received either 100 IU or 200 IU of r-FSH per day. Gonadotropin dose adjustment was allowed after day 4 of stimulation. Results: The average (SD) number of oocytes retrieved was 10.9 (5.4) and 12.2 (5.6) in the 100 IU and 200 IU group respectively (p = 0.067). The total doses of Puregon administered were 1887 IU and 2559 IU in the 100 IU and 200 IU group respectively. The number of transferable embryos, and the rates of pregnancies, cancelled cycles, miscarriages and adverse events including OHSS were comparable between the two groups. Conclusions: Women undergoing IVF have similar outcomes whether recombinant FSH is commenced in a dose of 100 IU or 200 IU for the first 4 days of stimulation. © 2005 Springer Science+Business Media, Inc.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know